A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

Cutaneous Oncology Program


New Clinical Trial for Patients with Melanoma That Has Spread to the Liver Opens at the University of Maryland Greenebaum Cancer Center

Dr. H. Richard Alexander, a surgical oncologist at the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) and expert in treating liver cancer, is testing a new therapy for patients with melanoma that has spread to the liver. The procedure, known as Percutaneous Hepatic Perfusion (PHP), involves targeting liver tumors with high doses of chemotherapy using a specially designed delivery system.

PHP is a way to circulate high doses of chemotherapy directly into the liver to treat patients with inoperable cancer. With this "closed loop" technique, only the liver is exposed to the chemotherapy, protecting other organs and minimizing the side effects of treatment.

About Dr. H. Richard Alexander

Dr. Alexander is an internationally recognized surgical oncologist and clinical researcher. He is recognized for developing innovative techniques to treat patients with advanced cancers of the gastrointestinal tract, especially the liver. He treats cancer patients at UMGCC and is associate chairman for clinical research in the University of Maryland Department of Surgery. Dr. Alexander came to the University of Maryland after spending 16 years at the National Institutes of Health, where he served as chief of the surgical metabolism section, chairman of the gastrointestinal malignancies section and deputy director of the NCI's Center for Cancer Research.

Learn more:

For more information about the Liver-Directed Therapies Program at the University of Maryland Marlene and Stewart Greenebaum Cancer Center, or any of our cancer programs or services, please call 1-800-888-8823.

This page was last updated on: December 15, 2010.